The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] Amygdalin inhibits the reaction [Ovalbumin results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] Amygdalin inhibits the reaction [Ovalbumin results in increased secretion of TGFB1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein]
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]
asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]]
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]]
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]]
[lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of HMOX1 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein]
asperuloside inhibits the reaction [[dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein]; asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]
asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]]
asperuloside inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; asperuloside inhibits the reaction [dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]]
[asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of NFE2L2 protein; asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of NFE2L2 protein] asperuloside affects the localization of NFE2L2 protein
asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]]
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; asperuloside inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein] calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein] calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein
calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA]
calycosin-7-O-beta-D-glucoside results in decreased degradation of and results in increased expression of HIF1A protein modified form; calycosin-7-O-beta-D-glucoside results in increased expression of and results in decreased degradation of HIF1A protein calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A protein
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein calycosin-7-O-beta-D-glucoside results in decreased expression of TXN mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein
daidzin results in increased expression of ACHE mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of ACHE mRNA]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of and results in increased activity of ACHE protein]; daidzin results in increased expression of and results in increased activity of ACHE protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA
daidzin inhibits the reaction [ALDH2 protein results in increased hydrolysis of 4-nitrophenyl acetate]; daidzin inhibits the reaction [ALDH2 protein results in increased oxidation of propionaldehyde]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA]
daidzin results in increased expression of PRIMA1 mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of PRIMA1 mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA
ABCB1 exon polymorphism affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein
ABCC1 protein affects the susceptibility to Etoposide Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] Etoposide results in increased expression of ABCC1 mRNA ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide [GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]
[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]
AKT1 protein modified form results in increased susceptibility to Etoposide Etoposide results in increased phosphorylation of AKT1 protein Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]
Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]
ALDOC protein affects the susceptibility to Etoposide [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein
calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein]
Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein Etoposide results in decreased expression of AREG mRNA
Etoposide results in increased phosphorylation of and results in increased activity of ATM protein Etoposide results in increased phosphorylation of ATM protein Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein]
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein Etoposide results in decreased expression of ATP6V1A protein
Etoposide results in increased activity of BAK1 protein BAK1 protein results in increased susceptibility to Etoposide BAK1 protein affects the susceptibility to Etoposide nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein] Etoposide affects the expression of BAK1 protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein] Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein BAX protein affects the susceptibility to Etoposide
Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein] BBC3 protein affects the susceptibility to Etoposide
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein]
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] Etoposide affects the expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Etoposide
Etoposide results in increased expression of BDNF mRNA HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA]
CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA]
BIRC2 protein affects the susceptibility to Etoposide BIRC2 protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of BIRC2 mRNA
BIRC3 protein results in decreased susceptibility to Etoposide Etoposide results in decreased expression of BIRC3 mRNA [Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA] BIRC5 protein results in decreased susceptibility to Etoposide
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein] Etoposide results in increased expression of BRCA1 protein Etoposide results in decreased expression of BRCA1 mRNA
TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein
Etoposide affects the expression of CASP3 protein Etoposide results in increased cleavage of CASP3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein]
[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein] 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein] CASP8 protein results in increased susceptibility to Etoposide
[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] Etoposide affects the expression of CASP9 protein
Etoposide affects the expression of and affects the localization of CCNA2 protein Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein
CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Etoposide
CD44 protein affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] CDK2 protein affects the susceptibility to Etoposide
[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein] Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]
Etoposide results in increased expression of CDKN1B protein wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein]
Etoposide results in increased expression of CDKN2A mRNA [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]
Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein Etoposide results in increased degradation of CEBPA protein
Etoposide results in increased phosphorylation of CHEK2 protein 4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]
Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]
Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]
CYP3A4 protein results in decreased methylation of Etoposide Etoposide results in increased expression of CYP3A4 mRNA [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide] CYP3A4 gene polymorphism affects the susceptibility to Etoposide; CYP3A4 protein affects the susceptibility to Etoposide
Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter]
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] Etoposide results in decreased expression of ERBB2 mRNA ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide ERBB2 protein affects the susceptibility to Etoposide
ESR2 protein results in increased susceptibility to Etoposide TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein]
DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein] Etoposide results in increased expression of FAS mRNA Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] Etoposide results in increased expression of FASL mRNA
FOS protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of FOS [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS]
Etoposide results in increased phosphorylation of FOXO1 protein wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein]
Etoposide results in increased phosphorylation of FOXO3 protein FOXO3 protein results in increased susceptibility to Etoposide [FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; Wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein]
Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein]
GADD45A protein results in increased susceptibility to Etoposide IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein] Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein Etoposide results in decreased expression of GANAB protein
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide
Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide]
BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein] [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein
Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide] GSTP1 gene polymorphism affects the susceptibility to Etoposide
Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein] H2AX protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter]
Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein]
Etoposide results in increased activity of HIPK2 protein HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] HIPK2 results in decreased susceptibility to Etoposide HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA]
HTATIP2 protein affects the susceptibility to Etoposide HTATIP2 protein results in increased susceptibility to Etoposide HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]
IKBKB protein affects the susceptibility to Etoposide DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]
IL4 protein results in decreased susceptibility to Etoposide [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein] Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein] Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein
KEAP1 protein results in decreased susceptibility to Etoposide KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein] KEAP1 mRNA results in increased susceptibility to Etoposide
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein Etoposide results in increased expression of KIT protein
Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]
KMT2A gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of KMT2A gene Etoposide results in increased cleavage of KMT2A gene
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA Etoposide results in decreased expression of LHX1 mRNA
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]
Etoposide results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Etoposide [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein] Etoposide results in decreased expression of MDM2 protein Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein] MDM2 promoter SNP results in decreased susceptibility to Etoposide
Etoposide results in decreased expression of MT2A protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]
Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA MYC protein results in increased susceptibility to Etoposide MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide MYCN protein results in decreased susceptibility to Etoposide
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein]
NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]
NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]
NQO1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NQO1 mRNA HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA]
Etoposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Etoposide Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA]
Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] NR1H3 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NR1H3 mRNA
NR1I2 protein affects the susceptibility to Etoposide [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]
NRIP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein
Etoposide results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
POLR1H protein results in decreased susceptibility to Etoposide Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide]
Etoposide results in increased expression of PPARGC1A mRNA Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein]
Etoposide results in increased expression of PPP1R13L mRNA Etoposide results in increased expression of and results in increased localization of PPP1R13L protein PPP1R13L results in decreased susceptibility to Etoposide
Etoposide results in increased phosphorylation of PRKDC protein PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]
PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [PTEN protein results in increased susceptibility to Etoposide]
Etoposide results in increased expression of PTGS2 protein PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein] Etoposide results in increased expression of RAD52 mRNA; Etoposide results in increased expression of RAD52 protein
[RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide]
RB1 protein affects the susceptibility to Etoposide Etoposide results in decreased phosphorylation of RB1 protein [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein]
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]
Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]]
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein]
Etoposide results in increased phosphorylation of SP1 protein Etoposide results in increased expression of SP1 mRNA Etoposide results in increased activity of SP1 protein cordycepin inhibits the reaction [Etoposide results in increased activity of SP1 protein]; cordycepin inhibits the reaction [Etoposide results in increased expression of SP1 mRNA] PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of SP1 protein]
Etoposide results in increased expression of SRXN1 mRNA; Etoposide results in increased expression of SRXN1 protein NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]
[STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of TFRC protein] Etoposide results in decreased expression of TFRC mRNA; Etoposide results in decreased expression of TFRC protein
TMSB4X protein results in decreased susceptibility to Etoposide TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]
Etoposide binds to TOP2A protein Etoposide analog results in decreased activity of TOP2A protein; Etoposide metabolite results in decreased activity of TOP2A protein; Etoposide results in decreased activity of TOP2A protein [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; delphinidin results in decreased susceptibility to [Etoposide affects the activity of TOP2A protein]; Etoposide metabolite inhibits the reaction [TOP2A protein binds to Nucleic Acids, Nucleotides, and Nucleosides]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]; TOP2A results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of TOP2A protein TOP2A protein results in increased susceptibility to Etoposide TOP2A protein modified form affects the susceptibility to Etoposide TOP2A gene mutant form results in decreased susceptibility to Etoposide; TOP2A protein mutant form results in decreased susceptibility to Etoposide
TOP2B protein mutant form results in decreased susceptibility to Etoposide Etoposide results in decreased activity of TOP2B protein TOP2B protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TOP2B protein TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] TOP2B protein mutant form results in increased susceptibility to Etoposide
Etoposide results in increased acetylation of TP53 protein; Etoposide results in increased acetylation of TP53 protein mutant form Etoposide affects the activity of TP53 protein; Etoposide metabolite affects the activity of TP53 protein Etoposide results in increased expression of TRP53 protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]; Etoposide results in increased phosphorylation of and results in increased activity of TRP53 protein; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]; TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] Etoposide results in increased activity of TP53 protein Etoposide results in increased phosphorylation of TP53 protein TRP53 protein affects the susceptibility to Etoposide Etoposide results in increased expression of TP53 protein [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of TP53 protein 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]; entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]; Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein]; Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter]; Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol]; Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein]; Etoposide results in increased expression of and results in increased acetylation of TP53 protein; Etoposide results in increased phosphorylation of and affects the localization of TP53 protein; Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein]; Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein]; Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein; Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] TP53 protein results in increased susceptibility to Etoposide; TP53 results in increased susceptibility to Etoposide
Etoposide results in increased expression of TP53BP1 protein pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of TP53BP1 protein]
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] Etoposide results in increased expression of TP73 mRNA; Etoposide results in increased expression of TP73 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; wortmannin promotes the reaction [Etoposide affects the localization of TPP2 protein]
Etoposide results in increased expression of TPT1 mRNA TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein] Etoposide results in increased expression of TPT1 mRNA; Etoposide results in increased expression of TPT1 protein TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]
Etoposide results in decreased expression of UBE2C mRNA; Etoposide results in decreased expression of UBE2C protein [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]
[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide VCAM1 protein results in decreased susceptibility to Etoposide
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] VDR gene polymorphism affects the susceptibility to Etoposide; VDR intron polymorphism affects the susceptibility to Etoposide
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]
XAF1 protein results in increased susceptibility to Etoposide Etoposide results in increased expression of XAF1 mRNA; Etoposide results in increased expression of XAF1 protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 protein] XRCC1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of XRCC1 mRNA; Etoposide results in increased expression of XRCC1 protein
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein] XRCC4 results in decreased susceptibility to Etoposide
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL18 protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL18 protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL1B protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL1B protein]
Chloroquine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]]; ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]] ginsenoside Rb1 results in decreased expression of SQSTM1 protein
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA]
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein]
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] ginsenoside Re results in decreased expression of AIF1 protein
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein]
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein]
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein]
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein ginsenoside Re results in increased phosphorylation of MAPK1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein ginsenoside Re results in increased phosphorylation of MAPK3 protein
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ginsenoside Re results in decreased expression of NOS2 protein
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re
ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein] ginsenoside Re results in decreased expression of PTAFR protein
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein
ginsenoside Re results in decreased expression of SCD mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA]
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein
SLCO1B2 protein binds to and results in increased transport of ginsenoside Re SLCO1B3 protein binds to and results in increased transport of ginsenoside Re
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re results in decreased activity of SOD1 protein
ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]]
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein]
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]]
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein]
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein] ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA]
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]
ginsenoside Rg1 results in increased expression of BAX protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA] ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein
ginsenoside Rg1 results in increased activity of CASP9 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein]
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA]
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein]
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA]
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA
gypenoside LXXV results in increased phosphorylation of AKT1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased phosphorylation of AKT1 protein]
gypenoside LXXV results in increased expression of and results in increased secretion of CTGF protein gypenoside LXXV results in increased expression of CTGF mRNA
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]
gypenoside LXXV results in decreased phosphorylation of IRS1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein]; gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]
gypenoside LXXV results in increased expression of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of PPARG protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV binds to and results in increased activity of PPARG protein]; gypenoside LXXV binds to and results in increased activity of PPARG protein
gypenoside LXXV affects the localization of SLC2A4 protein gypenoside LXXV results in increased expression of SLC2A4 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of SLC2A4 protein]
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]; gypenoside LXXV inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
Arbutin results in decreased expression of HSD3B1 mRNA Arbutin results in decreased expression of HSD3B1 mRNA; Arbutin results in decreased expression of HSD3B1 protein
Arbutin results in decreased activity of SRD5A1 protein Arbutin results in decreased expression of SRD5A1 mRNA; Arbutin results in decreased expression of SRD5A1 protein
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] astragalin inhibits the reaction [Bleomycin results in increased secretion of IL6 protein]
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
liquiritin inhibits the reaction [Monocrotaline results in increased expression of CCL2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]
liquiritin results in increased expression of GCLC protein liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLC mRNA]
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLM mRNA] liquiritin results in increased expression of GCLM protein
liquiritin inhibits the reaction [Monocrotaline results in increased activity of GPT protein] liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein]
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR protein]
liquiritin inhibits the reaction [Monocrotaline results in increased expression of HMOX1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of HMOX1 mRNA; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of HMOX1 protein]
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritin inhibits the reaction [Monocrotaline affects the expression of HSPD1 protein]
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA] liquiritin inhibits the reaction [Monocrotaline results in increased expression of IL6 mRNA]
NFE2L2 gene mutant form results in decreased susceptibility to liquiritin liquiritin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NFE2L2 protein] liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NFE2L2 mRNA]
liquiritin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NQO1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of NQO1 mRNA
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]
liquiritin inhibits the reaction [Monocrotaline results in increased expression of RELA protein] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein]
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 protein]
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 protein]
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 protein]
loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]
loganin inhibits the reaction [Glucose results in increased expression of CASP1 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of CASP1 protein]
loganin inhibits the reaction [Glucose results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [Glucose results in increased expression of GSDMD protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD protein]
loganin inhibits the reaction [Glucose results in increased expression of IL18 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL18 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL18 protein]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of IL18 mRNA]
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] loganin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL1B protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL1B protein]; loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 protein] loganin inhibits the reaction [Glucose results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of NLRP3 protein]
loganin affects the expression of RELA protein loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of RELA protein]
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of STAT3 protein] loganin inhibits the reaction [Lipopolysaccharides results in increased expression of STAT3 protein]
[luteolin-7-glucoside co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein luteolin-7-glucoside results in decreased phosphorylation of AKT1 protein
luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] luteolin-7-glucoside results in decreased expression of BCL2 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of CASP3 protein]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein] luteolin-7-glucoside results in increased activity of ESR1 protein
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein] luteolin-7-glucoside results in increased activity of ESR2 protein
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]
luteolin-7-glucoside results in decreased phosphorylation of MAPK1 protein 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK3 protein
luteolin-7-glucoside results in increased cleavage of PARP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]
malvidin-3-glucoside inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] malvidin-3-glucoside inhibits the reaction [TNF protein results in increased expression of SELE protein]
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]
monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] monotropein results in decreased degradation of NFKBIA protein
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA
[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACA protein]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ACACA mRNA
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of ACACB protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein
Neomycin results in decreased activity of ADA protein Tetrachlorodibenzodioxin inhibits the reaction [Neomycin results in decreased activity of ADA protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein
peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 mRNA]; peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 protein] Neomycin results in decreased expression of BCL2 mRNA; Neomycin results in decreased expression of BCL2 protein
BIX 01294 affects the reaction [Neomycin affects the cleavage of CASP3 protein]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 protein modified form] Neomycin results in increased expression of CASP3 mRNA; Neomycin results in increased expression of CASP3 protein modified form
Neomycin results in increased expression of CASP9 mRNA; Neomycin results in increased expression of CASP9 protein modified form peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 protein modified form]
CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin binds to and results in increased activity of CASR protein [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Neomycin binds to and results in increased activity of CASR protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2D2 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of CYP7A1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA
[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of FASN mRNA]
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of GCLM protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of GPBAR1 protein]
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased activity of GPT protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTA3 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of HMOX1 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of HTR4 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of HTR4 mRNA
[Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol S results in increased expression of IL18 protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of IL1B protein]]
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK1 protein modified form]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein Neomycin results in increased expression of MAPK3 protein modified form peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK3 protein modified form]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of NOS2 mRNA]]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR0B2 protein]
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in decreased expression of NR1H4 protein]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PDXK protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein
[Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SCD1 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein
Neomycin results in decreased expression of SHMT2 mRNA [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of SQSTM1 protein]
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol A results in increased expression of SREBF1 protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SST mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of SST mRNA
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of TNF protein]]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein]
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of TXN1 protein]
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein
notoginsenoside R1 results in increased expression of ABCB1 mRNA notoginsenoside R1 results in increased expression of ABCB1A mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP9 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein]
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein]
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein]
[notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein; notoginsenoside R1 results in increased phosphorylation of JAK1 protein
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]
notoginsenoside R1 results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased expression of MCL1 protein notoginsenoside R1 results in increased activity of MCL1 promoter [notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; cryptotanshinone inhibits the reaction [notoginsenoside R1 results in increased expression of MCL1 protein]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein
notoginsenoside R1 affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein]
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] notoginsenoside R1 results in increased activity of NR1I2 protein NR1I2 protein results in increased susceptibility to notoginsenoside R1
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein]
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]
[notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased phosphorylation of and results in increased localization of STAT3 protein [notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 results in decreased expression of TNF 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein]
notoginsenoside R1 results in increased expression of TXN1 protein notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of TXN1 protein]
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA]
oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]
oleuropein inhibits the reaction [Acrolein results in increased expression of BAX mRNA]; oleuropein inhibits the reaction [Acrolein results in increased expression of BAX protein] oleuropein inhibits the reaction [Rotenone results in increased expression of BAX protein]
oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 mRNA]; oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 protein]; oleuropein inhibits the reaction [decamethrin results in decreased expression of BCL2 protein] oleuropein affects the reaction [Rotenone results in decreased expression of BCL2 protein]
oleuropein results in increased activity of CAT protein oleuropein inhibits the reaction [Rotenone results in decreased activity of CAT protein] oleuropein inhibits the reaction [decamethrin results in decreased activity of CAT protein]
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased activity of GPT protein]; oleuropein inhibits the reaction [decamethrin results in increased expression of GPT protein]; oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein]
oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]
oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] oleuropein inhibits the reaction [decamethrin results in increased expression of PTGS2 protein]
oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein]; oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]; oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
[cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]
[bisphenol A diglycidyl ether co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein]
[bisphenol A diglycidyl ether co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein]
[cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA]
Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 mRNA]; Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 protein]
Phlorhizin results in increased expression of GSTM2 mRNA; Phlorhizin results in increased expression of GSTM5 mRNA Phlorhizin results in decreased expression of GSTM5 mRNA
[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL1B mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA]
[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA]
[bisphenol A diglycidyl ether co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of LEP mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA]
Phlorhizin inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS3 mRNA] Phlorhizin results in decreased expression of NOS3 mRNA
Phlorhizin inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside]; Phlorhizin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of Glucose SLC5A1 protein binds to Phlorhizin
[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA]
isosalipurposide affects the localization of NFE2L2 protein MAPK1 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein]; MAPK3 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein]
picrocrocin results in increased activity of TRPA1 protein 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [picrocrocin results in increased activity of TRPA1 protein]
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein]
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA isoquercitrin results in decreased activity of CYP1A1 protein
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA]
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA]
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA]
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA]
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA]
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide]
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein]
isoquercitrin results in decreased activity of CYP1A1 protein [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein]
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA]
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA]
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA]
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA]
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA]
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide]
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein] spiraeoside results in decreased expression of BCL2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]]; spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]
[Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside spiraeoside inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside]
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA]
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA]
rebaudioside A results in increased expression of MMP9 mRNA rebaudioside A inhibits the reaction [Thioacetamide results in increased activity of MMP9 protein]
4-((diethylamino)sulfonyl)benzoic acid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]; Probenecid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]
stevioside binds to and results in decreased activity of CYP3A4 protein stevioside results in increased expression of CYP3A4 mRNA; stevioside results in increased expression of CYP3A4 protein
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA]
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA]
Tannic Acid inhibits the reaction [aluminum acetate results in decreased activity of ACHE protein]; Tannic Acid inhibits the reaction [lead acetate results in decreased activity of ACHE protein]
Tannic Acid inhibits the reaction [Doxorubicin results in decreased activity of SOD1 protein]; Tannic Acid inhibits the reaction [Doxorubicin results in decreased expression of SOD1 mRNA]
CYP3A4 protein results in decreased methylation of Teniposide Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]
NR1H2 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA] Teniposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Teniposide
NR1H3 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Teniposide results in increased expression of and affects the localization of NR1H3 protein Teniposide results in increased expression of NR1H3 mRNA NR1H3 protein affects the susceptibility to Teniposide
Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]]
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein]
polydatin results in decreased localization of AHR protein polydatin promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein]
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA] polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]
cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] polydatin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]
polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] polydatin results in decreased secretion of CCL2 protein polydatin results in decreased expression of CCL2 mRNA
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA] polydatin results in decreased secretion of CXCL10 protein polydatin results in decreased expression of CXCL10 mRNA
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein]
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein]
polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] polydatin results in decreased expression of IL6 mRNA
polydatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein]
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK1 protein] polydatin results in decreased phosphorylation of MAPK1 protein
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK3 protein] polydatin results in decreased phosphorylation of MAPK3 protein
[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein; NFE2L2 protein affects the reaction [[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]] polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein]
polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein]
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased expression of NPPA protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [Phenylephrine results in increased expression of NPPA protein]
polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein] NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]]; polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]
[PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein; polydatin inhibits the reaction [Rotenone results in increased expression of PARK7 protein]
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased phosphorylation of PPP1R12A protein]; polydatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]
[polydatin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA polydatin results in decreased activity of PTGS2 protein
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]
polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein]
polydatin results in increased expression of and results in increased activity of SOD2 protein polydatin results in increased expression of SOD2 protein ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein]; fulvestrant inhibits the reaction [polydatin results in increased expression of SOD2 protein]
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; [polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein]
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA] polydatin results in decreased expression of TNF mRNA
polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein]; polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein]; polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein]
rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 protein]
rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 protein]
rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 protein]
rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein]
NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]
trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 protein] trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMOX1 protein]
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of IDH2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDH2 protein]
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
trilobatin promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin promotes the reaction [Isoflurane results in increased expression of NFE2L2 protein]
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 protein]
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 mRNA]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 protein]
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of SOD2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in increased acetylation of SOD2 protein]
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]